Gordon Blackhouse

Economic Evaluation of Donepezil for the Treatment of Alzheimer's Disease in Canada

BACKGROUND: Donepezil is a new drug recently approved in the United States and Canada for the treatment of Alzheimers disease (AD). We estimated the cost‐effectiveness of donepezil 5 mg daily as an adjunct to usual care in the management of persons with mild‐to‐moderate AD defined as a Mini‐Mental Health State Examination (MMSE) score in the range 10 to 26.

Cost-Effectiveness of the Implantable Cardioverter-Defibrillator Results From the Canadian Implantable Defibrillator Study (CIDS)

Background —In the Canadian Implantable Defibrillator Study (CIDS), we assessed the cost-effectiveness of the implantable cardioverter-defibrillator (ICD) in reducing the risk of death in survivors of previous ventricular tachycardia (VT) or fibrillation (VF). Methods and Results —Healthcare resource use was collected prospectively on the first 430 patients enrolled in CIDS (n=212 ICD, n=218 amiodarone). Mean cost per patient, adjusted for censoring, was computed for each group based on initial therapy assignment. Incremental cost-effectiveness of ICD therapy was computed as the ratio of the difference in cost (ICD minus amiodarone) to the difference in life expectancy (both discounted at 3% per year). All costs are in 1999 Canadian dollars (C

Cost-effectiveness of rhythm versus rate control in atrial fibrillation.

1 ≈ US

The economic burden of schizophrenia in Canada in 2004.

0.65). Over 6.3 years, mean cost per patient in the ICD group was C

The economic burden of schizophrenia in Canada.

87 715 versus C

The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia.

38 600 in the amiodarone group (difference C

Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

49 115; 95% CI C

Economic Evaluation of Long Term Management Strategies for Erosive Oesophagitis

25 502 to C

Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference

69 508). Life expectancy for the ICD group was 4.58 years versus 4.35 years for amiodarone (difference 0.23, 95% CI −0.09 to 0.55), for incremental cost-effectiveness of ICD therapy of C

Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records

213 543 per life-year gained. ICD benefit was greater in patients with low left ventricular ejection fraction (<35%), and cost-effectiveness in this group was more attractive (C